94°F
Sponsored by

Knocking Out Breast Cancer Recurrence with a Vaccine

<br>Putting breast cancer down for the count.

CONQUERING BREAST CANCER IS NOT AN EASY FEAT. 
ONCE IT'S BEATEN, THERE'S ALWAYS A CHANCE IT COULD COME BACK.
NOW DOCTORS ARE WORKING ON A NEW WAY TO HELP BREAST CANCER SURVIVORS WIN THE FIGHT ONCE AND FOR ALL.
KELLIE TROMBITAS IS A FIGHTER.
IT TOOK 33 ROUNDS OF RADIATION FOR HER TO KNOCK-OUT BREAST CANCER OVER TEN TOUGH MONTHS.
"Chemo takes a lot out of you. You're sick, I mean, it just makes you sick."
NOW, SHE'S EXCITED TO BE CANCER FREE.
"Ahh! Wonderful!"
BUT KELLIE STILL HAS CONCERNS.
"In the back of your mind you're always thinking, is it going to come back?"
SO SHE'S TAKING PART IN THIS CLINICAL TRIAL.
("We're going to do your vaccine today.")
TO TEST E-75. A VACCINE TO HELP PROTECT BREAST CANCER SURVIVORS FROM RECURRENCE. E-75 IS A PART OF THE HER-2 NEU PROTEIN. IT HELPS STIMULATE T-CELLS TO ATTACK CANCER CELLS. IN TRIALS, WOMEN INJECTED WITH THE VACCINE SAW A 50-PERCENT REDUCTION IN RECURRENCE. THE DRUG HERCEPTIN CAN DO THE SAME BUT IN A DIFFERENT WAY.
ONLY 20-PERCENT OF BREAST CANCER SURVIVORS, THOSE WITH HIGH LEVELS OF HER-2, CAN TAKE HERCEPTIN. E-75 DEVELOPER GEORGE PEOPLES SAYS THREE TIMES AS MANY SURVIVORS COULD BENEFIT FROM HIS VACCINE. IT TARGETS WOMEN LIKE KELLIE, WHO HAVE LOWER LEVELS OF HER-2.
"It allows us to use the vaccine for patients who are otherwise not eligible to receive Herceptin."
AS FOR KELLIE SHE'S STILL GETTING STRONGER.
FIGHTING TO KEEP CANCER FROM MAKING A COMEBACK.
 DOCTOR PEOPLES SAYS ONE DAY THE VACCINE COULD BE USED TO FIGHT LUNG, PROSTATE AND OVARIAN CANCERS THAT ALSO EXPRESS THE HER-2 PROTEIN.
RECRUITING FOR THE FINAL ROUND OF TRIALS FOR E-75 IS UNDERWAY RIGHT NOW.  
700 TO ONE-THOUSAND PARTICIPANTS IN DOZENS OF SITES ACROSS THE COUNTRY ARE NEEDED.
TO FIND OUT MORE ABOUT ENROLLING IN THE TRIAL GO TO WWW.NEUVAX.COM
Page: [[$index + 1]]
comments powered by Disqus

Poll

[[viewModel.Question]]

[[result.OptionText]] [[calculateVotePercent(result)]]%
[[settings.DelayedResultsMessage]]
Poll sponsored by